Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + carboplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Anlotinib + carboplatin + pemetrexed is a combination regimen used primarily in the treatment of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), particularly in patients who are EGFR/ALK wild-type or have developed resistance to prior therapies such as osimertinib. Anlotinib is a multi-target receptor tyrosine kinase inhibitor that inhibits angiogenesis and tumor proliferation by targeting VEGFR, FGFR, PDGFR, and c-Kit. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. Pemetrexed is an antifolate chemotherapy drug that disrupts folate-dependent metabolic processes essential for cell replication. The combination aims to synergistically inhibit tumor growth through both anti-angiogenic and cytotoxic mechanisms[2][3][5]. This regimen has been studied as first-line therapy followed by maintenance with anlotinib plus pemetrexed, showing promising efficacy and tolerability in clinical trials for advanced NSCLC[1][2][3].
- Brand names
- none
- Other names
- none
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)TS (Thymidylate synthase)VEGFR4 (Vascular endothelial growth factor Receptor-3)DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR (FGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on anlotinib + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + carboplatin + pemetrexed.